- Home
- IKT vs PBYI Comparison
IKT vs PBYI Comparison
Compare IKT & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKT
- PBYI
- Stock Information
- Founded
- IKT 2008
- PBYI 2010
- Country
- IKT United States
- PBYI United States
- Employees
- IKT N/A
- PBYI N/A
- Industry
- IKT Biotechnology: Pharmaceutical Preparations
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- IKT Health Care
- PBYI Health Care
- Exchange
- IKT Nasdaq
- PBYI Nasdaq
- Market Cap
- IKT 140.5M
- PBYI 164.3M
- IPO Year
- IKT 2020
- PBYI N/A
- Fundamental
- Price
- IKT $1.85
- PBYI $3.45
- Analyst Decision
- IKT Buy
- PBYI Strong Buy
- Analyst Count
- IKT 2
- PBYI 1
- Target Price
- IKT $8.00
- PBYI $7.00
- AVG Volume (30 Days)
- IKT 526.2K
- PBYI 307.3K
- Earning Date
- IKT 08-13-2025
- PBYI 07-31-2025
- Dividend Yield
- IKT N/A
- PBYI N/A
- EPS Growth
- IKT N/A
- PBYI 143.51
- EPS
- IKT N/A
- PBYI 0.77
- Revenue
- IKT N/A
- PBYI $232,709,000.00
- Revenue This Year
- IKT N/A
- PBYI N/A
- Revenue Next Year
- IKT N/A
- PBYI N/A
- P/E Ratio
- IKT N/A
- PBYI $4.43
- Revenue Growth
- IKT N/A
- PBYI 2.68
- 52 Week Low
- IKT $1.12
- PBYI $2.23
- 52 Week High
- IKT $4.20
- PBYI $4.13
- Technical
- Relative Strength Index (RSI)
- IKT 47.71
- PBYI 50.12
- Support Level
- IKT $1.80
- PBYI $3.26
- Resistance Level
- IKT $2.09
- PBYI $3.68
- Average True Range (ATR)
- IKT 0.14
- PBYI 0.12
- MACD
- IKT 0.03
- PBYI 0.00
- Stochastic Oscillator
- IKT 54.72
- PBYI 52.90
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.